ArticleThoracic cancer2023
Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Article in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 21 citations in OpenAlex.
- Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial.Cancer immunology, immunotherapy : CII · 2024Trial
- Tumor Necrosis on Routine Pretreatment CT as a Potential Prognostic Marker in Advanced NSCLC Treated With Immune Checkpoint Inhibitor Monotherapy: A Two-Center Retrospective Study.Thoracic cancer · 2026Article
- Article
- Association of baseline eosinophil counts with clinical prognosis in cancer patients undergoing immune checkpoint inhibitor therapy.iScience · 2026Article
- Article
- Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies.Journal of experimental & clinical cancer research : CR · 2026Review
- Predictive value of peripheral blood eosinophil levels and dynamics for efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer: a real-world study.Frontiers in immunology · 2026Article
- Application of NMR-based metabolomics and machine learning for non-invasive disease screening in dogs.Frontiers in veterinary science · 2026Article
- Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective Study.Biomedicines · 2025Article
- Variation in CBC-Derived Inflammatory Biomarkers Across Histologic Subtypes of Lung Cancer: Can Histology Guide Clinical Management?Diagnostics (Basel, Switzerland) · 2025Article
- Molecular subtype characteristics and development of prognostic model based on inflammation-related gene in lung adenocarcinoma.Discover oncology · 2025Article
- The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLCBiomolecules · 2025Review
- The causal relationship between eosinophil counts and hepatocellular carcinoma in East Asians: evidence from a Mendelian randomization study.Discover oncology · 2025Article
- Harnessing myeloid cells in cancer.Molecular cancer · 2025Review
- Complete blood count parameters as potential predictive factors of brain metastases in lung cancer.Frontiers in oncology · 2025Article
- Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis.Cancers · 2024Review
- Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade.Journal of experimental & clinical cancer research : CR · 2024Review
- The Enhanced Role of Eosinophils in Radiomics-Based Diagnosis of Microvascular Invasion and Its Association with the Immune Microenvironment in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Article
- Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma.Frontiers in immunology · 2024Article
- The causal nexus between diverse smoking statuses, potential therapeutic targets, and NSCLC: insights from Mendelian randomization and mediation analysis.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe peripheral blood eosinophil count prior to treatment has potential as a predictive biomarker for a beneficial clinical response to cancer immunotherapies. Therefore, the present study investigated the impact of the eosinophil count on overall survival (OS) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI).
methodsWe retrospectively reviewed all patients diagnosed with NSCLC and treated with ICI monotherapy between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University.
resultsA total of 166 patients were included. Fifty-five patients had an eosinophil count of less than 100 cells/μL (Eo < 100). Nighty-eight patients had an eosinophil count of 100 cells/μL or more, but less than 500 cells/μL (100 ≤ Eo < 500). Thirteen patients had an eosinophil count of 500 cells/μL or more (Eo ≥500). The median OS of all lung cancer patients was 476 days. The median OS of lung cancer patients with Eo <100, 100 ≤ Eo <500, and Eo ≥500 was 339, 667, and 143 days, respectively. A Kaplan-Meier univariate analysis showed a significant difference in OS between these three groups (p < 0.001). A Cox proportional regression analysis identified 100 ≤ Eo <500 (p = 0.04), ECOG PS score ≥ 2 (p = 0.02), tumor size ≥5 cm (p = 0.02), and PD-L1 ≥ 1% (p = 0.01) as independent predictors of OS.
conclusionOS was significantly longer in ICI-treated NSCLC patients with a pretreatment eosinophil count of 100 ≤ Eo <500 than in the other patients and, thus, has potential as a new predictive biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.